New Roche Smartphone BGM; Q4 ’18 Earnings Update

Roche hosted its Q4 ’18 earnings call and briefly discussed its diabetes device portfolio. For the first time, Roche disclosed it is developing a smartphone-based BGM called Accu-Chek SugarView 2.0 with an anticipated European launch in 2019. It is unclear if SugarView 1.0 was ever launched. According to Roche’s investor presentation, Accu-Chek SugarView 2.0 is “for non-insulin dependent T2 PwDs, allowing for meter-free blood glucose monitoring using Accu-Chek Active test strips and a smartphone camera.” Below, FENIX provides thoughts on the Accu-Chek SugarView 2.0, including product details, and other diabetes-related highlights from the call. 

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.